Morgan Stanley Gain Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,800 shares of GANX stock, worth $7,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,800

Previous 3,300 45.45%

Holding current value

$7,488

Previous $4,000 100.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.99 $1,410 - $2,985	1,500 Added 45.45%	4,800 $8,000
Q2 2024 Oct 17, 2024	BUY	$1.24 - $3.99 $620 - $1,995	500 Added 17.86%	3,300 $4,000
Q2 2024 Aug 14, 2024	BUY	$1.24 - $3.99 $620 - $1,995	500 Added 17.86%	3,300 $4,000
Q1 2024 Oct 17, 2024	SELL	$3.21 - $5.04 $1,605 - $2,520	-500 Reduced 15.15%	2,800 $10,000
Q4 2023 Aug 16, 2024	SELL	$2.07 - $3.4 $1,035 - $1,700	-500 Reduced 15.15%	2,800 $9,000
Q4 2023 Feb 13, 2024	BUY	$2.07 - $3.4 $3,104 - $5,100	1,500 Added 115.38%	2,800 $9,000
Q3 2023 Nov 15, 2023	BUY	$3.19 - $4.68 $1,595 - $2,340	500 Added 62.5%	1,300 $4,000
Q4 2022 Feb 14, 2023	SELL	$2.89 - $3.35 $728 - $844	-252 Reduced 23.95%	800 $2,000
Q3 2022 Nov 14, 2022	BUY	$3.17 - $4.21 $798 - $1,060	252 Added 31.5%	1,052 $4,000
Q2 2022 Oct 27, 2022	SELL	$2.56 - $4.56 $7 - $13	-3 Reduced 0.37%	800 $3,000
Q2 2022 Aug 15, 2022	SELL	$2.56 - $4.56 $7 - $13	-3 Reduced 0.37%	800 $3,000
Q1 2022 Oct 27, 2022	BUY	$3.15 - $5.59 $9 - $16	3 Added 0.38%	803 $3,000
Q1 2022 May 13, 2022	BUY	$3.15 - $5.59 $9 - $16	3 Added 0.38%	803 $3,000
Q3 2021 Nov 15, 2021	BUY	$7.01 - $10.26 $5,608 - $8,208	800 New	800 $6,000

Others Institutions Holding GANX

# of Institutions

Shares Held

2.39M

Call Options Held

10K

Put Options Held

View Full List

About Gain Therapeutics, Inc.

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $18.5M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

More about GANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account